Ziprazidone is approved for the treatment of schizophrenia, and acute mania and mixed states associated with bipolar disorder. Its intramuscular injection form is approved for acute agitation in schizophrenic patients for whom treatment with just ziprasidone is appropriate. The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown. However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism. As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown. References: Bouchette D, Pellegrini MV. Ziprasidone. 2017 Oct 9. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2017 Jun-. Available from .gov/books/NBK448157/ PubMed PMID: 28846230.

纯度：≥98%

CAS：146939-27-7